Kewaunee Scientific Corporation【KEQU】株式ニュース

Kewaunee Scientific Corporation Appoints Jorge Santos as Vice President of International Sales, Laboratory Products GroupApril 14, 2026 4:02 PM
PR Newswire (US)

STATESVILLE, N.C., April 14, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced the appointment of Jorge Santos as VP – International Sales – Lab Products Group, further strengthening the Company's commercial leadership as it accelerates growth in key global markets. Santos joins Kewaunee as the newest member of the Company's leadership team and will report directly to President and Chief Executive Officer, Thomas D. Hull III.

"Jorge's appointment marks a significant step forward in Kewaunee's growth strategy outside of the North American market," said Thomas D. Hull III, President & Chief Executive Officer of Kewaunee Scientific Corporation. "Historically, Kewaunee's focus outside of the North American market has been primarily within the Indian, Middle East, and Asia Pacific markets, with the Indian market being our largest, most successful market outside of the United States. With the addition of Nu Aire's diverse product portfolio and world class distribution partners into the Kewaunee family, new opportunities for global expansion exist and we are well positioned to take the next step in realizing these opportunities.""Jorge is an industry veteran based in Madrid, Spain, with a proven track record of delivering high quality laboratory projects worldwide. Jorge joins Kewaunee with over two decades of international commercial and operational leadership, having guided market expansions, built several multi-national sales organizations, and developed high-performing dealer networks across more than 25 countries. His experience spans Europe, the Middle East, Latin America, and Asia, making him uniquely positioned to support and further advance Kewaunee's next phase of global growth. His leadership will help accelerate our momentum as we look to capitalize on the capabilities that the combined Kewaunee and Nu Aire portfolio bring to our global customers.""Kewaunee is uniquely equipped to bring a more complete, integrated laboratory solution to the global market," Hull added. "With Jorge's experience and established relationships across Europe, the Middle East, and Asia, our path forward will be forged by strong leadership across our global organization and a clear vision for international expansion."As Kewaunee's presence expands globally, the Company remains firmly committed to the leadership and focus that have long driven success in its core markets. Domestic sales operations for both Kewaunee and Nu Aire will continue under the leadership of Ryan Noble, Vice President of Sales & Market Development, whose driven and customer-focused approach has been instrumental in maintaining consistent execution, strong engagement, and healthy growth across the Company's key markets. Noble's deep regional expertise and close relationships with Kewaunee's customers and partners remain central to the Company's commercial success.As the Indian economy continues to represent a robust, long term growth opportunity for the Company, B. Sathyamurthy (Sathya), President of Kewaunee International Group, will continue driving Kewaunee International Group operations. Sathya has spent more than 25 years building and scaling Kewaunee's International Group, helping establish India as an essential market within the Company's global operations. "Sathya and his team have developed a market-leading turnkey capability that has resulted in a solution-focused organization capable of serving customers across multiple end markets that require specialized engineering and furnishing expertise," Hull added. "These turnkey capabilities have set the team apart from the competition and created opportunities to expand the customer base served within India, capitalizing on a rapidly growing economy with significant infrastructure investments planned over the next decade."Hull further emphasized that the Company's global expansion will continue to be built on strong, market-tailored leadership and focused investment. "We see an exciting opportunity ahead for Kewaunee on the global stage. I believe we have the strongest commercial leadership in the industry, and the addition of Jorge's experience and leadership further strengthens our organization and will help us deepen our presence in the markets where the demand for advanced laboratory environments continues to accelerate."About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville, serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India, serving the local, Asian, and African markets.Kewaunee Scientific's newly acquired subsidiary, Nu Aire, Inc. (NuAire), is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, NuAire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/.This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the NuAire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the most recent fiscal year ended April 30, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.Contact:Donald T. Gardner III
704/871-3274

View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-corporation-appoints-jorge-santos-as-vice-president-of-international-sales-laboratory-products-group-302742110.htmlSOURCE Kewaunee Scientific Corporation

Original: Kewaunee Scientific Corporation Appoints Jorge Santos as Vice President of International Sales, Laboratory Products Group

Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026March 11, 2026 4:02 PM
PR Newswire (US)

STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended January 31, 2026.

Fiscal Year 2026 Third Quarter Results:Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter.The Company's order backlog was $183.2 million on January 31, 2026, as compared to $221.6 million on January 31, 2025, and $214.6 million on April 30, 2025.Domestic Segment - Domestic sales for the quarter were $50,953,000, a decrease of 2.0% from sales of $51,976,000 in the prior year quarter. Domestic segment net earnings were $2,290,000 compared to $2,876,000 in the prior year quarter. Domestic segment EBITDA was $4,096,000 compared to $5,249,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business.International Segment - International sales for the quarter were $18,446,000, an increase of 21.4% from sales of $15,191,000 in the prior year quarter. International segment net earnings were $1,256,000 compared to $476,000 in the prior year quarter. International segment EBITDA was $1,963,000 compared to $760,000 for the prior year quarter. International profitability increased when compared to the prior year period due to higher billings, principally in the Indian market.Corporate Segment – Corporate segment pre-tax net loss was $3,059,000 for the quarter, as compared to a pre-tax net loss of $3,025,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,264,000) compared to corporate segment EBITDA of ($2,275,000) for the prior year quarter. Corporate segment EBITDA remained relatively flat as the Company continues to make strategic investments in people, processes, and technology to further build out its Corporate platform and support continued growth.Total cash on hand on January 31, 2026, was $10,347,000, as compared to $17,164,000 on April 30, 2025. Working capital was $54,793,000, as compared to $58,441,000 at the end of the third quarter last year and $64,651,000 on April 30, 2025.The Company had short-term debt of $7,351,000 as of January 31, 2026, as compared to $4,773,000 on April 30, 2025. Long-term debt was $42,316,000 on January 31, 2026, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $25,988,000 of the long-term debt on January 31, 2026, and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $16,328,000 on January 31, 2026, as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio on January 31, 2026, was 0.68-to-1, as compared to 0.99-to-1 on April 30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on January 31, 2026, was 0.31-to-1, as compared to 0.57-to-1 on April 30, 2025."Following the successful turnaround of the business, we embarked on a strategy that accelerated inorganic growth, which led to the successful completion of the Company's acquisition of Nu Aire," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Since then, our teams have worked diligently to integrate Nu Aire into the Kewaunee family and position the business for meaningful growth and EBITDA contribution. We have also continued to invest in our corporate platform to support the next phase of our inorganic growth strategy. These investments include strengthening our corporate team, implementing a robust financial consolidation system, and enhancing our readiness to comply with the SEC's accelerated reporting requirements.""As is traditionally the case," Hull continued, "our third quarter results often represent our softest quarter due to the impact of the holiday schedule in the United States, a general slowdown of construction schedules in the winter months, and customers looking to wrap up any construction projects before the calendar year-end. This trend was further exacerbated by significant geopolitical and economic uncertainty, and by the volatility in project delivery timelines that we have previously discussed. Although the construction-related portion of our business has been soft this fiscal year, the addition of Nu Aire's end-user containment products has helped offset that softness. This dynamic validates our growth and diversification strategy and underscores the strength and resilience of our now broader laboratory products portfolio.""I am proud of how our team has responded to a year of challenging global dynamics. That our company was still able to deliver year-over-year growth on an as-reported basis underscores the value of our strategy and our commitment to long-term value creation."______________________1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation(Unaudited)($ in thousands) Quarter Ended January 31, 2025
Domestic
International
Corporate
ConsolidatedNet Earnings (Loss)
$                  2,876
$                    476
$                (1,998)
$                  1,354Add/(Less):

Interest Expense
322
26
789
1,137Interest Income
(1)
(130)
(81)
(212)Income Taxes
638
281
(1,027)
(108)Depreciation and Amortization
1,414
107
42
1,563EBITDA
$                  5,249
$                    760
$                (2,275)
$                  3,734Professional Fees2
1,012
—
982
1,994Adjusted EBITDA
$                  6,261
$                    760
$                (1,293)
$                  5,728

Quarter Ended January 31, 2026
Domestic
International
Corporate
ConsolidatedNet Earnings (Loss)
$                  2,290
$                  1,256
$                (2,854)
$                    692Add/(Less):

Interest Expense
307
16
789
1,112Interest Income
(2)
(117)
(15)
(134)Income Taxes
22
711
(205)
528Depreciation and Amortization
1,479
97
21
1,597EBITDA
$                  4,096
$                  1,963
$                (2,264)
$                  3,795Professional & Other Fees3
—
—
189
189Adjusted EBITDA
$                  4,096
$                  1,963
$                (2,075)
$                  3,984

Year to Date January 31, 2025
Domestic
International
Corporate
ConsolidatedNet Earnings (Loss)
$                10,271
$                  1,295
$                (5,011)
$                  6,555Add/(Less):

Interest Expense
1,176
66
809
2,051Interest Income
(1)
(437)
(410)
(848)Income Taxes
2,643
807
(2,450)
1,000Depreciation and Amortization
2,736
317
131
3,184EBITDA
$                16,825
$                  2,048
$                (6,931)
$                11,942Professional & Other Fees2
1,012
—
3,253
4,265Adjusted EBITDA
$                17,837
$                  2,048
$                (3,678)
$                16,207

Year to Date January 31, 2026
Domestic
International
Corporate
ConsolidatedNet Earnings (Loss)
$                10,609
$                  2,540
$                (6,919)
$                  6,230Add/(Less):

Interest Expense
931
39
2,261
3,231Interest Income
(4)
(428)
(54)
(486)Income Taxes
2,482
1,435
(1,713)
2,204Depreciation and Amortization
4,366
292
68
4,726EBITDA
$                18,384
$                  3,878
$                (6,357)
$                15,905Professional & Other Fees3
—
—
763
763Adjusted EBITDA
$                18,384
$                  3,878
$                (5,594)
$                16,668_____________________2 Professional and other fees incurred during the three and nine months ended January 31, 2025 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 20243 Professional and other fees incurred during the three and nine months ended January 31, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire Adjusted Consolidated Statement of Operations Reconciliation(Unaudited)($ in thousands, except per share amounts)
Three Months Ended January 31,
As Reported
2026
Professional &
Other Fees4
Adjusted
2026
Adjusted
2025Net sales$      69,399
$             —
$      69,399
$      67,167Cost of products sold50,854
—
50,854
47,934Gross profit18,545
—
18,545
19,233Operating expenses15,963
189
15,774
14,469Operating profit2,582
189
2,771
4,764Other income, net134
—
134
162Interest expense(1,112)
—
(1,112)
(1,137)Profit before income taxes1,604
189
1,793
3,789Income tax (benefit) expense528
44
572
502Net earnings1,076
145
1,221
3,287Less: Net earnings attributable to the non-controlling interest384
—
384
29Net earnings attributable to Kewaunee Scientific Corporation$           692
$           145
$           837
$        3,258

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

Basic$          0.24
$          0.05
$          0.29
$          1.13Diluted$          0.23
$          0.05
$          0.28
$          1.09
Nine Months Ended January 31,
As Reported
2026
Professional &
Other Fees4
Adjusted
2026
Adjusted
2025Net sales$    210,599
$             —
$    210,599
$    163,324Cost of products sold151,404
—
151,404
117,651Gross profit59,195
—
59,195
45,673Operating expenses47,696
763
46,933
31,954Operating profit11,499
763
12,262
13,719Other income, net709
—
709
752Interest expense(3,231)
—
(3,231)
(2,051)Profit before income taxes8,977
763
9,740
12,420Income tax (benefit) expense2,204
174
2,378
2,161Net earnings6,773
589
7,362
10,259Less: Net earnings attributable to the non-controlling interest543
—
543
81Net earnings attributable to Kewaunee Scientific Corporation$        6,230
$           589
$        6,819
$      10,178

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

Basic$          2.18
$          0.21
$          2.38
$          3.55Diluted$          2.09
$          0.20
$          2.29
$          3.42_______________________4 Professional and other fees incurred during the three and nine months ended January 31, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire, including the estimated tax impactAbout Non-GAAP Measures The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration of the Company's newly acquired subsidiary, Nu Aire, Inc., and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's integration of its newly acquired subsidiary, Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to interest expense and interest income, income taxes, depreciation, amortization or the costs incurred related to the integration of Nu Aire, Inc., which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.Learn more at the companies' websites, located at https://www.kewaunee.com and https://www.nuaire.com/. This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.Kewaunee Scientific CorporationCondensed Consolidated Statements of Operations(Unaudited)($ and shares in thousands, except per share amounts)
Three Months EndedJanuary 31,
Nine Months EndedJanuary 31,
2026
2025
2026
2025Net sales$       69,399
$       67,167
$    210,599
$     163,324Cost of products sold50,854
48,788
151,404
118,505Gross profit18,545
18,379
59,195
44,819Operating expenses15,963
16,129
47,696
35,560Operating profit2,582
2,250
11,499
9,259Other income, net134
162
709
428Interest expense(1,112)
(1,137)
(3,231)
(2,051)Profit before income taxes1,604
1,275
8,977
7,636Income tax expense (benefit)528
(108)
2,204
1,000Net earnings1,076
1,383
6,773
6,636Less: Net earnings attributable to the non-controlling interest384
29
543
81Net earnings attributable to Kewaunee Scientific Corporation$            692
$         1,354
$        6,230
$         6,555

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

Basic$           0.24
$           0.47
$          2.18
$           2.29Diluted$           0.23
$           0.45
$          2.09
$           2.20Weighted average number of common shares outstanding

Basic2,866
2,872
2,861
2,864Diluted2,983
2,995
2,979
2,979 Kewaunee Scientific CorporationCondensed Consolidated Balance Sheets($ in thousands)
January 31, 2026
April 30, 2025
(Unaudited)

Assets

Cash and cash equivalents$            8,153
$          14,942Restricted cash2,194
2,222Receivables, less allowances54,131
62,384Inventories32,907
32,849Prepaid expenses and other current assets6,193
5,966Total Current Assets103,578
118,363Net property, plant and equipment22,610
23,174Right of use assets10,449
12,965Deferred income taxes3,570
3,994Net intangible assets16,679
17,831Goodwill12,487
12,487Other assets6,588
5,840Total Assets$        175,961
$        194,654

Liabilities and Stockholders' Equity

Short-term borrowings$            1,542
$              986Current portion of lease obligations3,248
3,371Current portion of financing liability847
788Current portion of term loans4,893
2,903Accounts payable23,641
27,033Other current liabilities14,614
18,631Total Current Liabilities48,785
53,712Long-term portion of lease obligations6,796
8,946Long-term portion of financing liability25,988
26,632Long-term portion of seller note—
23,537Long-term portion of term loans16,028
10,412Other non-current liabilities5,836
5,170Total Liabilities103,433
128,409Kewaunee Scientific Corporation Equity70,675
64,457Non-controlling interest1,853
1,788Total Stockholders' Equity72,528
66,245Total Liabilities and Stockholders' Equity$        175,961
$        194,654   Contact: Donald T. Gardner III
704/871-3274

View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-third-quarter-of-fiscal-year-2026-302711429.htmlSOURCE Kewaunee Scientific Corporation

Original: Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026